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Abstract: Breast cancer development is associated with macrophage infiltration and differentiation
in the tumor microenvironment. Our previous study highlights the crucial function of reactive
oxygen species (ROS) in enhancing macrophage infiltration during the disruption of mammary
tissue polarity. However, the regulation of ROS and ROS-associated macrophage infiltration in
breast cancer has not been fully determined. Previous studies identified retinoid orphan nuclear
receptor alpha (RORα) as a potential tumor suppressor in human breast cancer. In the present
study, we showed that retinoid orphan nuclear receptor alpha (RORα) significantly decreased ROS
levels and inhibited ROS-mediated cytokine expression in breast cancer cells. RORα expression in
mammary epithelial cells inhibited macrophage infiltration by repressing ROS generation in the
co-culture assay. Using gene co-expression and chromatin immunoprecipitation (ChIP) analyses, we
identified complex I subunits NDUFS6 and NDUFA11 as RORα targets that mediated its function
in suppressing superoxide generation in mitochondria. Notably, the expression of RORα in 4T1
cells significantly inhibited cancer metastasis, reduced macrophage accumulation, and enhanced
M1-like macrophage differentiation in tumor tissue. In addition, reduced RORα expression in breast
cancer tissue was associated with an increased incidence of cancer metastasis. These results provide
additional insights into cancer-associated inflammation, and identify RORα as a potential target to
suppress ROS-induced mammary tumor progression.
Keywords: tumor microenvironment; reactive oxygen species; macrophage; breast cancer; orphan
nuclear receptor; complex I
1. Introduction
Inflammation is a hallmark of cancer, featured by infiltration of tumor-associated
macrophages. Macrophages are the most abundant immune-related stromal cells in the
tumor microenvironment [1]. The accumulation of macrophages in tumors correlates with
poor prognosis in breast cancer patients and drives cancer development and progression by
inducing angiogenesis and suppressing immune response [2–4]. Macrophage accumulation
occurs at an early stage of breast cancer development [5,6]. Therefore, the inhibition of
macrophage-induced chronic inflammation may offer a promising strategy to prevent or
repress cancer progression.
The disruption of the polarized epithelial tissue structure is an event that occurs at
the early stage of breast cancer development [7,8], which is accompanied by a significant
remodeling of the tissue microenvironment. We showed previously that the disruption
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of the polarized acinar structure was accompanied by increased production of (ROS) [9].
Treatment with antioxidant agents reduces ROS levels and reprograms non-polarized
breast cancer cells to form polarized spheroids in a three-dimensional (3D) culture [9],
indicating that the elevation of ROS is necessary to disrupt polarized acinar formation.
ROS and associated oxidative stress are the driving force of cancer development and
progression [10–12]. ROS are byproducts of normal metabolism through the electron
transport chain [13]. It was shown that electron leakage from complex I and III in the
mitochondria is the major source of ROS [14,15].
Increased ROS generation is associated with inflammation and macrophage infiltra-
tion [16,17]. In the 3D co-culture assay, we showed that reducing ROS levels in breast
cancer cells inhibited macrophage infiltration [9]. These results suggest a potential link
between the disruption of tissue polarity, ROS production, and cancer-associated inflam-
mation. Mitochondria are considered the major source of ROS. However, how ROS pro-
duction in mitochondria contributes to cancer-associated macrophage infiltration is not
completely understood.
RORα is a member of the orphan nuclear receptor factor family and regulates gene
expression by binding to ROR response elements (ROREs) [18]. The RORA gene maps
to 15q22.2, a large common fragile site that is often deleted in cancer cells [19]. There
are four isoforms being identified for human RORα proteins, and we showed previously
that isoform 1 and 4 of RORα were expressed in human mammary epithelial cells [20].
By comparing gene expression profiles between polarized and disorganized mammary
organoids, we have identified RORα as a positive regulator of tissue polarity [20]. RORα
expression is reduced during cancer development [19–21]. Notably, the reduced RORα
expression in primary breast cancer correlated with poor prognosis. The restoration of
RORα expression in cancer cells suppresses cancer progression in 3D cultures and in mouse
models [20]. These findings suggest that RORα is a novel, potent tumor suppressor.
RORα deficient mice suffer from immune abnormalities and display a stronger in-
flammatory response compared to wild-type mice [22]. The NF-κB pathway is a critical
regulator of cytokine expression and inflammation [23,24]. The primary regulation of the
NF-κB pathway is through association of NF-κB complexes with their inhibitor, I kappa B
proteins. I kappa B binds to p65 or p50 subunit and inhibits their nuclear translocation. It
has been shown that RORα negatively regulates the NF-κB signaling pathway by reducing
p65 nuclear translocation [25,26]. This evidence suggests the potential function of RORα in
inflammation; however, the exact roles of RORα in breast cancer-associated inflammation
and macrophage infiltration remain to be determined.
In the present study, we showed that RORα expression inhibited ROS generation,
cancer-associated macrophage infiltration, and breast cancer metastasis. We also identified
complex I genes as RORα targets that mediate its function in regulating redox balance.
These findings reveal a novel link between RORα downregulation, ROS generation, and
cancer progression.
2. Results
2.1. RORα Inhibits Activation of Inflammation Gene Signature and Expression of Cytokines in
Breast Cancer Cells
By comparing gene expression profiles between polarized and non-polarized mam-
mary epithelial organoids, we identified RORα as a major regulator of mammary tissue
polarity with inhibitory activity on tumor invasion [20]. Invasive breast cancer cell lines,
including MDA-MB-231, MDA-MB-157, and BT-549, form the aggressive branching struc-
tures in 3D culture [20]. We found that the expression of RORα in these breast cancer cell
lines significantly reduced the number of invasive branches and suppressed invasive tumor
growth in 3D culture (Figure 1A and Supplemental Figure S1A).
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Gene set enrichment analysis (GSEA) data showed that the inflammatory pathway was inhibited by 
RORα in MDA-MB-231 and MDA-MB-157 cells in 3D culture. (D) Heatmap showing cytokine gene 
expression in control and RORα-expressing MDA-MB-231 cells in 3D culture. (E) Real-time RT-PCR 
quantified mRNA levels of cytokines genes in control and RORα-expressing MDA-MB-231 and 
MDA-MB-157 cells; results are presented as mean ± SEM; n=4, **** p < 0.0001, *** p < 0.001, ** p < 0.01, 
* p < 0.05, one-way ANOVA test. (F) Real-time RT-PCR quantified cytokines gene expression in 
control and RORα-silenced S1 cells; results are presented as mean ± SEM; n=4, ** p <0.01, * p <0.05, 
student’s t-tests. (G) ELISA analysis quantified the protein levels of IL-6 in the conditioned medium 
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(A) Phase images showing control and RORα-expressing MDA-MB-231, MDA-MB-157, and BT-549
cells in 3D culture after being plated for 4 days. Bar: 100 µm. (B) Heatmap showing different gene ex-
pression profiles in control and RORα-expressing MDA-MB-231 and MDA-MB-157 cells. (C) Gene set
enrichment analysis (GSEA) data showed that the inflammatory pathway was inhibited by RORα in
MDA-MB-231 and MDA-MB-157 cells in 3D culture. (D) Heatmap showing cytokine gene expression
in control and RORα-expressing MDA-MB-231 cells in 3D culture. (E) Real-time RT-PCR quantified
mRNA levels of cytokines genes in control and RORα-expressing MDA-MB-231 and MDA-MB-157
cells; results are presented as mean ± SEM; n = 4, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05,
one-way AN VA test. (F) Real-time RT-PCR quantified cytokines gene expression in control and
RORα-silenced S1 cells; results are presented as mean ± SEM; n = 4, ** p <0.01, * p <0.05, student’s
t-tests. (G) ELISA analysis quantified the protein levels of IL-6 in the conditioned medium collected
from control and RORα-silenced S1 and MCF-10A cells, and from control and RORα-expressing
MDA-MB-231 cells; results are presented as mean ± SEM; n = 3, ** p < 0.01, * p < 0.05, one-way
ANOVA test.
To determine how RORα suppresses breast cancer progression, we performed gene
expression profiling analysis in MDA-MB-231 and MDA-MB-157 cells with Affymetrix
Exon Array, and identified many genes being differentially expressed in control and RORα-
expressing cells (Figure 1B and Supplementary Table S1). The gene set enrichment analysis
(GSEA) showed that the inflammatory pathway and expression of cytokine genes were
inhibited by RORα in 3D culture (Figure 1C,D). Real-time RT-PCR data confirmed the
results from microarray (Figure 1E). We also found that silencing RORα in S1 cells, a
non-malignant mammary epithelial cell line, enhanced cytokine expression (Figure 1F).
To further determine whether RORα inhibits cytokine protein expression and secretion,
we quantified IL-6 levels in the conditioned medium collected from RORα-silenced and
RORα-expressing cells with ELISA assay. Silencing RORα in S1 cells and MCF-10A cells
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increased the IL-6 protein levels in the conditioned medium, while overexpression of RORα
decreased the level in breast cancer cells (Figure 1G and Supplemental Figure S1B). These
results indicate that RORα expression suppresses the expression of the inflammation gene
signature and cytokines in mammary epithelial cells.
2.2. RORα Inhibits ROS Production by Repressing the Expression of Complex I Genes
We previously showed that ROS production was elevated in non-polarized mammary
epithelial cells, which in turn enhanced cytokine expression and monocyte infiltration
in 3D culture [9]. Since silencing RORα induces the disruption of mammary tissue po-
larity [20], we asked whether the downregulation of RORα induces cytokine expression
by elevating ROS levels. The knockdown of RORα significantly elevated ROS levels in
non-malignant mammary epithelial cells, while introducing RORα in breast cancer cells
reduced ROS production (Figure 2A and Supplemental Figure S2). Notably, reducing ROS
levels in the RORα-silenced MCF-10A cells with antioxidant n-Acetyl-L-cysteine (NAC)
treatment suppressed cytokine gene expression (Figure 2B). These results indicate that ROS
mediates RORα function in repressing the expression of cytokines and the inflammation
gene signature.




Figure 2. ROS mediates RORα function in repressing cytokine expression. (A) FACS analysis quan-
tified ROS levels in control and RORα-silenced MCF-10A cells, the top 50% of cell population in 
control group was gated as “ROS High”; results are presented as mean ± SEM; n = 4, **** p < 0.0001, 
student’s t-tests. (B) Real-time RT-PCR quantified mRNA levels of cytokines genes in RORα-si-
lenced MCF-10A cells cultured with or without NAC (4 µM) treatment for 48h; results are presented 
as mean ± SEM; n = 4, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, one-way ANOVA test. (C) 
Table showing the significantly negative correlation between RORα and complex I gene mRNA 
levels in human breast cancer tissue, gene expression data were derived from the TCGA breast can-
cer dataset. (D) Real-time RT-PCR quantified mRNA levels of mitochondrial complex I genes in 
control and RORα-expressing MDA-MB-231 cells; results are presented as mean ± SEM; n = 4, *** p 
< 0.001, ** p < 0.01, * p < 0.05, student’s t-tests. (E) Real-time RT-PCR quantified mRNA levels of 
mitochondrial complex I genes in control and RORα-silenced MCF-10A cells; results are presented 
as mean ± SEM; n=4, ** p < 0.01, * p < 0.05, student’s t-tests. (F) FACS quantification of ROS levels in 
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mean ± SEM; n = 4, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, one-way ANOVA test. (G) FACS 
quantification of ROS levels in control or RORα-silenced or RORα&NDUFS6-silenced or 
RORα&NDUFA11-silenced MCF-10A cells; results are presented as mean ± SEM; n = 4, **** p < 
0.0001, *** p < 0.001, one-way ANOVA test. (H) Real-time RT-PCR quantified mRNA levels of cyto-
kines genes; NDUFS6 or NDUFA11 knockdown partially rescued the expression of these genes in 
RORα-silenced MCF-10A cells; results are presented as mean ± SEM; n = 4, **** p < 0.0001, *** p < 
0.001, ** p < 0.01, one-way ANOVA test. 
Electron leakage from the respiration chain increases superoxide anion production 
[27]. To determine whether the RORα/complex I axis inhibits electron leakage in mito-
chondria, we measured superoxide anion levels with mitoSOX red in control and RORα-
expressing breast cancer cells [28]. Silencing RORα significantly increased mitochondrial 
Figure 2. S mediates RORα functio in pressing cytokine expression. (A) FACS analysis
quantified ROS levels in control and RORα-silenced MCF-10A cells, the top 50% of cell population in
control group was gated as “ROS High”; results are presented as mean ± SEM; n = 4, **** p < 0.0001,
student’s t-tests. (B) Real-time RT-PCR quantified mRNA levels of cytokines genes in RORα-silenced
MCF-10A cells cultured with or without NAC (4 µM) treatment for 48h; results are presented as
mean± SEM; n = 4, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, one-way ANOVA test. (C) Table
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showing the significantly negative correlation between RORα and complex I gene mRNA levels
in human breast cancer tissue, gene expression data were derived from the TCGA breast can-
cer dataset. (D) Real-time RT-PCR quantified mRNA levels of mitochondrial complex I genes in
control and RORα-expressing MDA-MB-231 cells; results are presented as mean ± SEM; n = 4,
*** p < 0.001, ** p < 0.01, * p < 0.05, student’s t-tests. (E) Real-time RT-PCR quantified mRNA lev-
els of mitochondrial complex I genes in control and RORα-silenced MCF-10A cells; results are
presented as mean ± SEM; n = 4, ** p < 0.01, * p < 0.05, student’s t-tests. (F) FACS quantification
of ROS levels in control or NDUFS6-silenced or NDUFA11-silenced MDA-MB-231 cells; results
are presented as mean ± SEM; n = 4, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, one-way
ANOVA test. (G) FACS quantification of ROS levels in control or RORα-silenced or RORα&NDUFS6-
silenced or RORα&NDUFA11-silenced MCF-10A cells; results are presented as mean ± SEM; n = 4,
**** p < 0.0001, *** p < 0.001, one-way ANOVA test. (H) Real-time RT-PCR quantified mRNA levels
of cytokines genes; NDUFS6 or NDUFA11 knockdown partially rescued the expression of these
genes in RORα-silenced MCF-10A cells; results are presented as mean ± SEM; n = 4, **** p < 0.0001,
*** p < 0.001, ** p < 0.01, one-way ANOVA test.
To determine how RORα regulates ROS generation and cytokine expression, we
performed gene co-expression analysis using the breast cancer TCGA dataset. We showed
that the expression of mitochondrial complex I genes was negatively associated with RORα
levels in human breast cancer tissues (Figure 2C). Real-time RT-PCR data showed that
the introduction of RORα in MDA-MB-231 cells significantly inhibited the expression of
multiple complex I genes (Figure 2D and Supplemental Figure S3), while silencing RORα
elevated the mRNA levels of these genes in MCF-10A cells (Figure 2E).
It was shown that electron leakage from complex I is one of the major sources of
ROS [14,15]. We asked whether RORα suppresses ROS generation by repressing complex
I gene expression. We performed a focused screening and found that silencing NDUFS6
or NDUFA11 significantly decreased ROS levels in MDA-MB 231-cells (Figure 2F and
Supplemental Figure S4). To further determine whether these two genes mediate RORα
function in regulating ROS, we knocked down NDUFS6 and NDUFA11 expression in
RORα-silenced MCF-10A cells. Reducing NDUFS6 or NDUFA11 expression partially
suppressed ROS generation induced by RORα silencing (Figure 2G). The knockdown of
NDUFS6 or NDUFA11 also repressed the expression of IL-6, IL-8, CXCL1, and CXCL3 in
RORα-silenced MCF-10A cells (Figure 2H). These results indicate that RORα suppresses
ROS generation and cytokine expression, in part, by repressing the expression of complex
I genes.
Electron leakage from the respiration chain increases superoxide anion production [27].
To determine whether the RORα/complex I axis inhibits electron leakage in mitochondria,
we measured superoxide anion levels with mitoSOX red in control and RORα-expressing
breast cancer cells [28]. Silencing RORα significantly increased mitochondrial superox-
ide levels in MCF-10A cells, while expression of RORα in MDA-MB-231 cells reduced
the superoxide accumulation (Figure 3A). We also found that silencing NDUFS6 or ND-
UFA11 significantly decreased superoxide levels in MDA-MB-231 cells (Figure 3B). Notably,
reducing NDUFS6 or NDUFA11 expression suppressed the superoxide generation in
RORα-silenced MCF-10A cells (Figure 3C).
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Figure 3. RORα inhibits ROS production by repressing the expression of c mplex I genes. (A) F CS quantification
of mitochondrial superoxide levels in control and RORα-silenced MCF-10A cells, and in control and RORα-expressing
MDA-MB-231 cells; results are presented as mean ± SEM; n = 4, ** p < 0.01, student’s t-tests. (B) FACS quantification
of mitochondrial superoxide levels in control or NDUFS6-silenced or NDUFA11-silenced MDA-MB-231 cells; results are
presented as mean ± SEM; n = 4, *** p < 0.001, ** p < 0.01, one-way ANOVA test. (C) FACS quantification of mitochondrial
superoxide levels in control or RORα-silenced or RORα&NDUFS6-silenced or RORα&NDUFA11-silenced MCF-10A cells;
results are presented as mean ± SEM; n = 6, **** p < 0.0001, *** p < 0.001, ** p< 0.01, one-way ANOVA test. (D) Seahorse
analysis quantified OCR in control and RORα-silenced S1 cells. (E) Seahorse analysis quantified OC in control and RORα-
silenced S1 cells; results are pre nted a mean ± SEM; n = 12, ** p < 0.01, student’s t-tests. (F) Seahors analysis quantified
OCR in control and RORα-expressing MDA-MB-157 cells; results are presented as mean± SEM; n = 12, ** p < 0.01, student’s
t-tests.
The electron leakage in mitochondria is associated with oxygen consumption [15,29].
The oxygen consumption rate (OCR) can be quantified in real-time using the Seahorse
XF96 Extracellular Flux Analyzer. Seahorse analysis showed that silencing RORα sig-
nificantly reduced OCR in non-malignant mammary epithelial cells (Figure 3D,E). In
contrast, the overexpression of RORα in breast cancer cells elevated OCR (Figure 3F).
We also found that silencing NDUFS6 and NDUFA11 increased OCR in breast cancer
cells (Supplemental Figure S5). These results suggest that the inactivation of RORα in
breast cancer cells enhances electron leakage in mitochondria by increasing NDUFS6 and
NDUFA11 expression.
To determine how RORα suppresses the expression of complex I genes, we analyzed
the sequence of NDAFS6 and NDAUFA11 genes, then identified several potential RORE in
their promoter regions (Figure 4A). ChIP data showed that RORα bound to the promoter
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regions of NDUFS6 and NDUFA11 genes (Figure 4B). We also found that the expression of
RORα negatively correlated with NDUFS6 and NDUFA11 mRNA levels in human breast
cancer tissue (TCGA breast cancer dataset) (Figure 4C). These data suggest that RORα
binds to RORE in the promoter region of NDUFS6 and NDUFA11, and suppresses the
gene transcription.
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and is associated with reduced gene transcription (Figure 5A). Notably, low levels of 
RORα mRNA in breast cancer tissue are associated with short metastasis-free survival 
(Figure 5B). 
To determine whether RORα expression suppresses breast cancer metastasis, we in-
jected control and RORα-expressing MDA-MB-231-luc cells (luciferase-labeled) in SCID 
mice via the tail vein. RORα expression significantly inhibited MDA-MB-231 cell coloni-
Figure 4. RORα binds to ROREs in NDUFS6 and NDUFA11 promote regions. (A) Scheme showing
the potential RORE in NDAFS6 and NDAUFA11 g nes. The red box presents potential RORE
in their ~2000 bp promoter regions. (B) Bar graph showing the relative ChIP DNA enrichment in
control and RORα-overexpression MDA-MB-231 cells. After normalization to input, the relative
enrichment of ChIP DNA was calculated in both groups by dividing with the value of the control
group; results are presented as mean ± SEM; n = 4, **** p < 0.0001, *** p < 0.001, student’s t-tests.
(C) Dot plots showing the negative correlation between mRNA levels of NDUFS6 or NDUFA11 and
RORα expression in human breast cancer tissues (gene expression data were derived from the TCGA
breast cancer dataset).
2.3. RORα Expression Inhibits Mammary Tumor Metastasis and Macrophage Infiltration in
Tumor Tissue
We showed previously that reduced RORα expression was associated with poor prog-
nosis in breast cancer patients [20]. To determine how RORα expression is regulated during
breast cancer development, we analyzed DNA copy number at RORA gene loci. The loss
of RORA gene copy number was detected in 30% of human breast cancer tissue and is
associated with reduced gene transcriptio (Figure 5A). Notably, low levels of RORα mRNA
in breast cancer tissue are associated with sh rt m tastasis-free survival (Figur 5B).
To determine whether RORα expression suppresses breast cancer metastasis, we in-
jected cont ol and RORα-expressing MDA-MB-231-luc cells (luciferase-labeled) in SCID
mice via the tail vein. RORα expression significantly inhibited MDA-MB-231 cell colo-
nizat on in he lung (Figure 5C and Supplemental Figure S6). The orthotopi mammary
tumor model in immune competent mice is more physiologically relevant for studying
cancer metastasis. Therefore, we further examined the roles of RORα in regulating cancer
metastasis with the 4T1 model. The control and RORα-expressing 4T1 cells were injected
into the BALB/c mice at the fourth mammary fat pad. Once tumors reached 1000 mm3,
they were surgically removed. After three weeks, metastatic lesions in the lung were
quantified. We found that the expression of RORα also significantly inhibited the lung
metastasis of 4T1 cells in BALB/c mice (Figure 5D).
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macrophage infiltration and differentiation. We wondered whether RORα regulates mac-
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Figure 5. RORα expression inhibits breast cancer metastasis in mice. (A) Reduction of RORα ex-
pression was negatively associated with LOH in human breast cancer tissue, n = 860, **** p < 0.0001,
one-way ANOVA test. (B) Kaplan-Meier survival analysis showing reduced RORα mRNA level is
associated with short distant recurrence-free survival, n = 6365. (C) IVIS images (left) and quantifica-
tion data (right) showing lung colonization of control and RORα-expressing MDA-MB-231-luc cells
in SCID mice; results are presented as mean± SEM; n = 6, * p < 0.05, student’s t-tests. (D) HE staining
(left) and quantification (right) of metastatic lesions of 4T1 cells in the lung; results are presented as
mean ± SEM; n = 4, * p < 0.05, student’s t-tests. Bar: 100 µm.
Data from gene expression profiling showed that RORα inhibited the inflamma-
tory pathway (Figure 1C). The inflammation in the mammary tumor tissue is associated
with macrophage infiltration and differentiation. We wondered whether RORα regulates
macrophage accumulation in 4T1 xenografts. Immunohistochemistry analysis showed that
F4/80 positive cells were reduced in RORα-expressing 4T1 tumor sections (Figure 6A).
Quantified data from FACS analysis showed that RORα expression significantly reduced
the number of total macrophages in 4T1 tumor tissues; interestingly, the portion of M1-like
macrophages was increased upon RORα expression (Figure 6B–D, Supplemental Figure S7).
It was shown that M1-like macrophages suppress tumor progression and enhance immune
response [30]. These results suggest that RORα suppresses breast cancer metastasis at least
partially by reducing macrophage accumulation and by enhancing M1-like differentiation.
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Next, we utilized a co-cultured system to determine how RORα inhibits macrophage
infiltration. Control and RORα-expressing DA- B-231 cells were cultured in the lower
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the upper chamber. We found that expressing RORα in breast cancer cells significantly
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cha ber (Figure 7 ). Interestingly, antioxidant treat ent suppressed the -1 cell
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Among the RORα-repressed cytokines, IL-6 is a pro-inflammatory factor that induces
macrophage/monocyte infiltration and differentiation [31,32]. We found that the addition
of IL-6 rescued the THP-1 cell migration that was suppressed by RORα- expressing MDA-
MB-231 cells in the co-culture assay (Figure 7C). These results suggest that the function of
RORα in suppressing macrophage infiltration is at least partially mediated by IL-6.
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showing the migration of THP-1 cells in the co-culture assay. THP-1 cells were co-cultured with RORα-silenced MCF-10A
cells treated with or without NAC (4 µM) for 24 h; results are presented as mean ± SEM; n = 4, **** p < 0.0001, student’s
t-tests. Bar: 100 µm. (C) Quantification data showing the migration of THP-1 cells in the co-culture assay. THP-1 cells were
co-cultured with RORα-expressing MDA-MB-231 cells in the presence or absence of IL-6 (20 ng/mL); results are presented
as mean ± SEM; n = 4, **** p < 0.0001, one-way ANOVA test. (D) Scheme showing the molecular mechanism by which
RORα suppresses ROS-associated macrophage accumulation and cancer progression.
3. Discussion
RORα was identified as a potential tumor suppressor in breast cancer [33]; however,
the molecular and cellular mechanisms by which it suppresses cancer progression are
not fully understood. In the present study, we showed that the downregulation of RORα
in breast cancer cells induced ROS generation by enhancing complex I gene expression.
The increased ROS levels in mammary epithelial cells is sufficient to induce cytokine
expression and macrophage migration. We also found that RORα expression inhibited
cancer-associated macrophage infiltration and breast cancer metastasis in vivo. These
results identified new roles of RORα in repressing cancer metastasis and ROS-associated in-
flammation.
Macrophage infiltration is detected at the early stage of breast cancer development [5,6,34].
Macrophages also accumulate around the terminal end buds of mammary glands rather
than the polarized ductal epithelial cells [35,36]. One common feature shared by the
terminal end buds and the mammary tumor is the presence of multilayer non-polarized
epithelial cells [37,38]. Using 3D culture assay, we further confirmed the association
between the disruption of tissue polarity and macrophage infiltration and identified ROS as
a potential molecule link between mammary tissue polarity and macrophage infiltration [9].
Reduced RORα expression is detected in non-polarized breast cancer cells and terminal
end buds [20,39]. In addition, RORα expression is sufficient to restore tissue polarity
in malignant mammary epithelial cells [20]. We showed that RORα suppressed ROS
generation and subsequently inhibited cytokine expression and macrophage infiltration.
These results imply that RORα is the major regulator of ROS production and inflammation
associated with the disruption of tissue polarity (Figure 7D).
It is well established that the mitochondria respiration chain generates significant
amounts of superoxide [40]. Superoxide reacts with manganese SOD (MnSOD) in the
mitochondrial matrix to generate H2O2, which can cross the mitochondrial outer membrane
to access cytosolic targets [41]. A study in the nonalcoholic steatohepatitis model showed
that RORα reduced ROS levels in hepatocytes and suppressed hepatic oxidative stress,
which is accompanied with induction SOD2 and Gpx1 [42]. We showed that RORα
expression was negatively associated with mRNA levels of complex I genes in human breast
cancer tissues. Using ChIP analysis and functional rescue experiments, we demonstrate
that RORα suppressed ROS generation by directly repressing the expression of NDUFS6
and NDUFA11. The negative correlation between RORα expression and mRNA levels
of NDUFS6 and NDUFA11 suggests that these two genes are the major targets of RORα
mediating its function in ROS regulation during breast cancer progression.
It was reported that inhibiting the activity of complex I enhances the ROS production
and promotes cancer cells’ migration and invasion [43]. Mammalian complex I contains
45 subunits, and the roles of complex I subunits in ROS generation are more compli-
cated. We showed that silencing NDUFS6 and NDUFA11 suppressed superoxide and ROS
generation in breast cancer cells. In addition, the upregulation of complex I subunits in
RORα-silenced mammary epithelial cells was accompanied by reduced OCR, while silenc-
ing NDUFS6 and NDUFA11 increased OCR in breast cancer cells (Supplemental Figure S4).
These results imply that an increased expression of NDUFS6 and NDUFA11 in mammary
epithelial cells enhances the electron leakage in mitochondria. A study in neurons and
astrocytes provides a possible explanation as to the different functions of complex I in
ROS generation. Mitochondrial complex I in neurons mainly embeds in supercomplexes
with highly efficient mitochondrial respiration and low ROS production. However, the
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abundance of free complex I is higher in astrocytes, which leads to the significantly high
ROS production [44]. These data suggest that the complex I status dictates its roles in ROS
production. It would be interesting to determine whether the reduction of RORα in cancer
cells leads to the accumulation of free complex I in the future.
Increased ROS production induces the activation of redox-sensitive transcription fac-
tors, such as HIF-1α and NF-κB, expression of pro-inflammatory cytokines, and release
of inflammasomes. Mitochondrial-derived oxidative stress is associated with chronic in-
flammation and cancer progression. Mitochondrial-derived ROS also contributes to the
production of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α [41]. It was reported
that RORα suppresses the NF-κB pathway and inflammation [45]. Our data suggest that
ROS is the major mediator of RORα function in regulating cytokine expression and cancer-
associated macrophage infiltration. Cancer-associated macrophages create an inflammatory
environment to stimulate angiogenesis, promote tumor growth, and enhance tumor cell
migration and invasion [46,47]. IL-6 is an important cytokine that regulates macrophage
infiltration and differentiation; it can also promote breast cancer metastasis by enhancing
epithelial–mesenchymal transition [32,48]. We showed that IL-6 is one of the cytokines
suppressed by RORα in mammary epithelial cells. The results from the co-culture experi-
ments suggest that RORα inhibits macrophage accumulation in breast cancer tissue at least
partially through IL-6 repression.
In summary, our data reveal the new function of RORα in repressing ROS generation
by inhibiting the expression of complex I genes. Restoring RORα expression suppresses can-
cer metastasis and ROS-associated inflammation; therefore, enhancing RORα expression or
inducing RORα activation with agonists is a potential strategy to suppress ROS-associated
cancer progression.
4. Materials and Methods
4.1. Antibodies and Reagents
Matrigel was purchased from BD Bioscience (Bedford, MA, USA). ShRNA constructs
selectively targeting NDUFS6, NDUFA7, NDUFA9, and NDUFA11 were purchased from
Sigma Aldrich (MISSION shRNA library, St. Louis, MO, USA). Recombinant human IL-6
was purchased from Peprotech (Cranbury, NJ, USA; 200-06). NAC (A7250) was purchased
from Sigma Aldrich (St. Louis, MO, USA). Antibody CD16/32 (101302, clone:93) was
purchased from BioLegend (San Diego, CA, USA). Antibodies F4/80 (1950719, clone: BM8),
CD11c (2011154, clone: N418), CD45 (2055168, clone: 104), CD11b (2011193, clone: M1/70),
CD86 (1987724, clone: GL1), and CD206 (2073756, clone: MR6F3) were purchased from
Invitrogen (Waltham, MA, USA). Antibody RORα (E0713) was purchased from Santa
Cruz Biotechnology (Dallas, TX, USA). Antibodies Flag (F1804) and tubulin (AB9354) were
purchased from Sigma Aldrich (St. Louis, MO, USA). Antibody NDUFA11 (17879-1-AP)
was purchased from Proteintech.
4.2. Cell Lines and Culture Conditions
The MDA-MB-231 cells were cultured in DMEM/F12 (Sigma Aldrich, St. Louis, MO,
USA; D8437) with 10% FBS (Sigma Aldrich, St. Louis, MO, USA; F2442) and 1% Pen/Strep
(Sigma Aldrich, St. Louis, MO, USA; P4333). BT549 cells were cultured in RPMI-1640
(Sigma Aldrich, St. Louis, MO, USA; R8758) with 10% FBS and 1% Pen/Strep. MDA-
MB-157 cells were cultured in DMEM (Sigma Aldrich, St. Louis, MO, USA; D6429) with
10% FBS and 1% Pen/Strep. The HMT-3522 S1 cells were cultured in DMEM/F12 with
250 ng/mL insulin, 10 µg/mL transferrin, 2.6 ng/mL sodium selenite, 10−10 M β-estradiol,
1.4 µM hydrocortisone, 5 µg/mL prolactin, and 10 ng/mL EGF. MCF-10A cells were
cultured in DMEM/F12 with 5% horse serum, 20 ng/mL EGF, 0.5 mg/mL hydrocortisone,
100 ng/mL cholera toxin, 10 µg/mL insulin, and 1% Pen/Strep. THP-1 cells were cultured
in RPMI-1640 with 10% FBS, 1% Pen/Strep, and 0.05 mM 2-mercaptoethanol. HEK293 FT
cells (A kind gift from Dr. Mina J Bissell, Lawrence Berkeley National Laboratory) were
cultured in DMEM with 10% FBS, 0.1 mM Non-Essential Amino Acids (Sigma Aldrich, St.
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Louis, MO, USA; M7145), 6 mM L-glutamine (VWR, Atlanta, GA, USA; 20J1956675), 1 mM
Sodium Pyruvate (Sigma Aldrich, St. Louis, MO, USA; S8636), and 1% Pen/Strep. The
cells were grown in a humidified incubator at 37°C with 5% CO2. All the cells were tested
for mycoplasma contamination every two months.
4.3. 3D Culture
A three-dimensional lrECM on-top culture was performed as previously described [9].
150 ul of Matrigel (Corning, NY, USA; 6347014) was plated on the bottom of a 24-well
plate; MDA-MB-231 cells, MDA-MB-157 cells, and BT-549 cells (0.4 × 105 cells per well)
were seeded on the top of the Matrigel layer, and the additional medium containing 10%
Matrigel was added on the top.
4.4. Co-Culture Assay
After MDA-MB-231 cells and MCF-10A cells were cultured in a 24-well plate for 24 h,
R18-dyed THP-1 cells or differentiated THP-1 cells (M0 macrophage) were seeded to a
transwell plate (Thermo Fisher Scientific, Rockford, IL, USA; 140629). THP-1 cells were
differentiated to M0 macrophages with 150 nM PMA (Sigma Aldrich, St. Louis, MO, USA;
P1585) treatment. Fluorescence images were taken 24 h later with an Eclipse 80i microscope
(Nikon, Tokyo, Japan). The pictures were taken under fixed exposure conditions.
4.5. Microarray Analysis and Quantitative RT-PCR
Control and RORα-expressing MDA-MB 231 and MDA-MB 157 cells were isolated
from 3D cultures as previously described [39]. Total cellular RNA was extracted using an
RNeasy minikit with on-column DNase digestion (Qiagen, Hilden, Germany). Affymetrix
microarray analysis was performed using the Affymetrix HuGene-1.0 highthroughput
array (HTA) GeneChip system. Preprocessing, normalization, and filtering were performed
using the R Bioconductor. The R package limma [49] was used to perform differential
expression analysis comparing control and RORα-expressing for each of the two cell lines,
157 and 231, separately. Significant differentially expressed genes were determined as false
discovery rate q-value < 0.20. A heatmap was generated for results visualization. Gene set
enrichment analysis was performed with GSEA v2.07 [50].
Complementary DNA was synthesized using the SuperScriptTM III First-Strand Syn-
thesis kit (Invitrogen, Waltham, MA, USA; 18-080-051) from 1 µg RNA samples. Quan-
titative RT-PCR was carried out with SYBR Green PCR Master Mix reagents using an
StepOnePlusTM Real-Time PCR System (Thermo Fisher Scientific, Rockford, IL, USA;
4376600). Thermal cycling was conducted at 95 ◦C for 30 s, followed by 40 cycles of 5 s
amplification at 95 ◦C, 55 ◦C for 30 s, and 72 ◦C for 15 s. The relative quantification of gene
expression for each sample was analyzed by the threshold cycle (CT) method. Information
on the primers used for the amplification of RORα, IL-6, IL-8, IL-24, IL-32, Cxcl1, Cxcl2,
Cxcl3, Cxcl5, Cxcl10, NDUFS6, NDUFA7, NDUFA9, NDUFA11, and 18S ribosomal RNA is
given in Supplementary Table S2.
4.6. Seahorse Assay
MDA-MB-231 cells (shcontrol, shNDUFS6, shNDUFA11), S1 cells (shcontrol, shRORα),
and MDA-MB-157 cells (control, RORα-expressing) were seeded to a seahorse XF96 mi-
croplate (10,000 cells per well). After 24 h, the cell culture microplate was placed into a
37 ◦C non-CO2 incubator for 1 h. Then, the mitochondrial respiration was measured in the
XF Analyzer according to the Agilent Seahorse XF96 Cell Mito Stress Test Assay manual.
4.7. ROS and Superoxide FACS Analysis
According to the CellROX Deep Red Flow Cytometry Assay Kit manual (Invitrogen,
Waltham, MA, USA; C10491), cells were trypsinized and resuspended at a concentration
of 0.5 × 105 cells/mL. The Deep Red reagent was added to the cell samples at 1 µM and
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incubated for 45 min at 37 ◦C and protected from light. One microliter propidium iodide
(1 mg/mL) was added to the cell samples and incubated on ice for FACS analysis.
According to the MitoSOXTM Red manual (Invitrogen, Waltham, MA, USA; M36008),
cells were trypsinized and resuspended at a concentration of 0.5 × 105 cells/mL. The
MitoSOXTM reagent was added to the cell samples at 5 µM and incubated for 30 min at
37 ◦C and protected from light. Then cells were resuspended in PBS for FACS analysis.
FACS analysis was done with Becton Dickinson LSR II (San Diego, CA, USA) and data
were analyzed by FlowJo.
4.8. Chromatin Immunoprecipitation (ChIP) Assay
Flag-tagged RORA cDNA were cloned into pCDH1 plasmid and generated expression
vector pCDH1-RORα-Flag. HEK293 FT cells were transfected with pCDH1 or pCDH1-
RORα-Flag plus packaging lentivector using FuGENE (Promega, Madison, WI, USA;
0000356676). MDA-MB-231 cells were infected with lentivirus and selected by puromycin
48 h after infection. Vector control and RORα-expressing MDA-MB-231 cells were cross-
linked using formaldehyde for the ChIP assay. The ChIP assay was performed based on the
Upstate Biotechnology ChIP protocol, with a few modifications [51]. After formaldehyde
cross-linking, nuclei were isolated with a nuclear isolation kit (Sigma Aldrich, St. Louis,
MO, USA) and resuspended in ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mMTris-HCl
[pH8.0]) containing protease inhibitor cocktail. Protein-DNA complexes were immuno-
precipitated as per the Upstate protocol. Ten percent of the extracted chromatin was
aliquoted as input, and 5% of input was used as a template for qPCR. Isolated DNA was
then analyzed by quantitative PCR using the following primers: NDUFS6 promoter, 5′-
AAGGTTTCGCACACCATTGC-3′and 5′-GATTCAGGTGGTCACCCGTT-3′, and NDUFA11
promoter, 5′-GCTATGGCTCCCAATGCCTA-3′ and 5′- CGTGTGCACTTGTATAGACGC-3′.
4.9. Mouse Experiments
For the xenograft experiments, 6-week-old female BALB/c mice were randomly
grouped and injected with 1 × 106 control or RORα-expressing 4T1 cells at the 4th mam-
mary fat pad. The tumors were measured with a caliper every other day. The tumor volume
(mm3) was estimated using the formula [volume = π × (width)2 × (length) /6]. Once
tumors reached 1000 mm3 (25 days after tumor cell implantation), the primary tumors
were removed by surgery. Xenograft tumor sections were de-paraffinized and rehydrated.
An immunohistochemistry analysis of F4/80 positive cells was performed as described
previously [52]. Three weeks after primary tumor removal, the lung tissue was collected
for fixation and hematoxylin and eosin (HE) staining for the detection of metastases in the
lungs. Images were taken with a Nikon microscope.
For the lung colonization experiments, 6-week-old female severe combined immun-
odeficient (SCID) mice were randomly grouped and injected with 1 × 106 control or
RORα-expressing MDA-MB-231-luc cells via the tail vein. To detect lung metastasis, bio-
luminescent images were taken every week after injection using in vivo imaging system
(IVIS). All mouse experiments were approved by the University of Kentucky Institutional
Animal Care and Use Committee.
4.10. Tumor Infiltrating Lymphocytes Isolation and FACS Analysis
Primary tumor tissues from control and RORα-expressing 4T1 xenografts were di-
gested with collagenase (Sigma Aldrich, St. Louis, MO, USA; C6885). Single cells were
isolated and blocked by CD16/32 for 10 min and stained by cell surface markers F4/80,
CD11c, CD45, CD11b, CD86, and CD206 for 30 min at 4 ◦C, and protected from light.
The cells were then resuspended for FACS analysis. Macrophages were identified as
DAPI-, CD45+, CD11b+, CD11c-, and F4/80+. The macrophages were then gated for M1
(CD86+CD206-) and M2 (CD86- CD206+) [53].
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4.11. Kaplan-Meier Survival Analysis and Other Statistical Analysis
The clinical relevance of reduced RORα expression was assessed by analyzing mRNA
levels of RORα and patient survival using the published microarray data generated from
6,365 human breast cancer tissue samples [54]. Significant differences in distant metastasis-
free survival time were assessed with the Kaplan–Meier survival analysis and the Cox
proportional hazard (log-rank) test.
All experiments were repeated at least twice. Inferential statistics were used to compare
data sets from different experimental groups and reported data were the mean ± standard
error of mean (SEM). Student’s t-tests (two groups) and one-way ANOVA (three or more
groups) were used to determine the significant differences between means and were
performed with Prism 6.01 (Graph Pad Software, San Diego, CA, USA). The minimum
statistical significance was set at p < 0.05.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms221910665/s1.
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